M&A Deal Summary

Savara Pharmaceuticals Acquires Mast Therapeutics

On January 7, 2017, Savara Pharmaceuticals acquired life science company Mast Therapeutics

Acquisition Highlights
  • This is Savara Pharmaceuticals’ 2nd transaction in the Life Science sector.
  • This is Savara Pharmaceuticals’ 1st transaction in the United States.
  • This is Savara Pharmaceuticals’ 1st transaction in California.

M&A Deal Summary
Date 2017-01-07
Target Mast Therapeutics
Sector Life Science
Buyer(s) Savara Pharmaceuticals
Deal Type Merger
Advisor(s) ROTH Capital Partners LLC (Financial)
DLA Piper (Legal)

Target

Mast Therapeutics

San Diego, California, United States
Mast Therapeutics, Inc.is a bio pharmaceutical company. It is a provider of MAST (Molecular Adhesion and Sealant Technology) platform for clinical, nonclinical and manufacturing experience with purified and non-purified poloxamers to develop MST-188.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Savara Pharmaceuticals

Austin, Texas, United States
Category Company
Sector Life Science
DESCRIPTION

Savara Pharmaceuticals is a specialty pharmaceutical company focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Merger) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2017) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-21 Serendex Pharmaceuticals A/S

Horsholm, Denmark

Serendex Pharmaceuticals A/S is a developer of novel inhalation therapies for the treatment of patients with rare respiratory conditions.

Buy -
Mergr

Product

Company

Legal